CoChat

How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

The Nanotechnology Risk Assessment Working Group in the Center for Drug Evaluation and Research (CDER) within the United States Food and Drug Administration (FDA) was established to assess the potential impact of nanotechnology on drug products. One of the working group's major initiatives has been to conduct a comprehensive risk management exercise regarding the potential impact of nanomaterial pharmaceutical ingredients and excipients on drug product quality, safety, and efficacy. This exercise concluded that current review practices and regulatory guidance are capable of detecting and managing the potential risks to quality, safety, and efficacy when a drug product incorporates a nanomaterial. However, three risk management areas were identified for continued focus during the review of drug products containing nanomaterials: (1) the understanding of how to perform the characterization of nanomaterial properties and the analytical methods used for this characterization, (2) the adequacy of in vitro tests to evaluate drug product performance for drug products containing nanomaterials, and (3) the understanding of properties arising from nanomaterials that may result in different toxicity and biodistribution profiles for drug products containing nanomaterials. CDER continues to actively track the incorporation of nanomaterials in drug products and the methodologies used to characterize them, in order to continuously improve the readiness of our science- and risk-based review…

Overview

Integrity signals

Registry

Crossref · 10.1208/s12248-017-0084-6

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Research works printed but not linked: 2

  1. Christopher R Beekman, MM., Adil Mohammad, Adarsh Gandhi, Dajun Sun, Wenlei Jiang, Robert Lionberger, Rodney Rouse, Vikram Patel., Determining the bio-distribution of colloidal iron drug products in rats by inductively coupled plasma mass spectrometry (ICP-MS). NYAS workshop, Equivalence of complex drug products: Scientific and regulatory challenges (Nov 9, 2016) 2016.
  2. Wu M, Sun D, Tyner K, Jiang W, Rouse R. Comparative in vitro cellular uptake study on reference and generic sodium ferric gluconate in mononuclear phagocyte systems. 2016 NYAS Workshop, Equivalence of complex drug products; Scientific and Regulatory challenges (Nov 9, 2016) 2016.

Cited by

See all 33

Metadata

Authors
Tyner, K. M., Zheng, N., Choi, S., Xu, X., Zou, P., Jiang, W., Guo, C., & Cruz, C. N.
Affiliations
United States Food and Drug Administration (US)
Corresponding author
Cruz, Celia N.
Venue
The AAPS Journal
Published
2017-04-18
Volume
19
Issue
4
Pages
1071-1083
ISSN
1550-7416 (ISSN-L)
OpenAlex
W2607360117
Cited by
33
References
49
Citations by year
2026: 5 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 5 · 2019: 3 · 2017: 2
FWCI
0.20
Type
journal article
Language
en
Open access
closed
Locations
  • The AAPS Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
U.S. Department of Health and Human Services
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Materials Science › General Materials Science › Nanotechnology research and applications
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
nanotechnology, risk management, nanomaterial characterization, nanomaterial toxicity, tissue distribution, regulatory guidelines, regulatory research, FDA Center for Drug Evaluation and Research
MeSH terms
United States, United States Food and Drug Administration, Drug Approval, Risk Assessment, Nanotechnology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities. https://app.cochat.ai/papers/10.1208/s12248-017-0084-6
The paper
Tyner, K. M., Zheng, N., Choi, S., Xu, X., Zou, P., Jiang, W., Guo, C., & Cruz, C. N. (2017). How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities. The AAPS Journal. https://doi.org/10.1208/s12248-017-0084-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.